![Ali Baker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ali Baker
Inversor de Capital Privado en Flare Therapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Daphne Karydas | F | 49 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 años |
Lorence Kim | M | 49 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Robert J. Sims | M | - |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Jigar Raythatha | M | 47 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Abbie Celniker | M | 65 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
David Kaufman | M | 51 |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 4 años |
Justin Rubbo | M | - |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 2 años |
Arnav Mehta | M | - |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 años |
Sophia Fox | F | - |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Tara Reagan | F | - |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Steven Paul | M | 73 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Vyas Ramanan | M | - |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 4 años |
Aaron Davis | M | 45 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Jakob Loven | M | 46 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Michael Meyers | M | 74 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 1 años |
Mark Angelino | M | 51 |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Kevin Munnelly | M | 52 |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Marc Crowley | M | - |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Kevin Starr | M | 61 |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 14 años |
Amit Rakhit | M | 54 |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Jeffrey Walsh | M | 58 |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 21 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Ali Baker
- Red Personal